Autopsy report · NCT01578343

Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma

“we collected data of a total of 19 patients for an interim analysis. but there are less than 7 responses out of the initial 19 patients.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 3 years 8 months before it stopped.
• 20 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Samsung Medical Center

Sponsor type

University, hospital or other

Conditions

Mantle Cell Lymphoma

Interventions

Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat

Participants

20

Sites

1

Countries

South Korea

Trials that died the same way

• Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
  “Interim analysis indicated low probability of clinically significant result” (66% match in meaning)
• Novel Interventions in HIV-1 Infection
  “Data from the 12 patients recruited has now been analysed, and it has been determined that it is sufficient to meet the study objectives.” (65% match in meaning)
• Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy
  “The investigation was prematurely interrupted with 65 patients enrolled due to difficulties in recruiting patients. However the results observed in the interim analysis demonstrate the performance of the investigational device.” (64% match in meaning)
• Trial Comparing Start Stimulation of Recombinant Follicle Stimulating Hormone (rFSH) on Cycle Day 2 Versus Cycle Day 5 in In Vitro Fertilization (IVF)
  “Inclusion of the study didn't go as fast as expected. Expect: 234 patients in 1 year in 2 centers. After 1,5 year only 147 patients were recruited.” (64% match in meaning)
• A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys
  “Interim results suggested a concern for patient outcomes and safety” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.